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ABSTRACT
Objectives: Public and patient engagement (PPE) is
fundamental to healthcare research. To facilitate
effective engagement in novel point-of-care tests
(POCTs), the test and downstream consequences of
the result need to be considered. Sequential simulation
(SqS) is a tool to represent patient journeys and the
effects of intervention at each and subsequent stages.
This case study presents a process evaluation of SqS
as a tool for PPE in the development of a volatile
organic compound-based breath test POCT for the
diagnosis of oesophagogastric (OG) cancer.
Setting: Three 3-hour workshops in central London.
Participants: 38 members of public attended a
workshop, 26 (68%) had no prior experience of the OG
cancer diagnostic pathway.
Interventions: Clinical pathway SqS was developed
from a storyboard of a patient, played by an actor,
noticing symptoms of oesophageal cancer and following
a typical diagnostic pathway. The proposed breath testing
strategy was then introduced and incorporated into a
second SqS to demonstrate pathway impact. Facilitated
group discussions followed each SqS.
Primary and secondary outcome measures:
Evaluation was conducted through pre-event and
postevent questionnaires, field notes and analysis of
audiovisual recordings.
Results: 38 participants attended a workshop. All
participants agreed they were able to contribute to
discussions and like the idea of an OG cancer breath
test. Five themes emerged related to the proposed new
breath test including awareness of OG cancer, barriers
to testing and diagnosis, design of new test device, new
clinical pathway and placement of test device. 3 themes
emerged related to the use of SqS: participatory
engagement, simulation and empathetic engagement,
and why participants attended.
Conclusions: SqS facilitated a shared immersive
experience for participants and researchers that led to
the coconstruction of knowledge that will guide future
research activities and be of value to stakeholders
concerned with the invention and adoption of POCT.
BACKGROUND
Public and patient engagement (PPE) is a
fundamental component of healthcare
research and actively encouraged by the
Department of Health and major funding
bodies. PPE refers to the dissemination of
information and knowledge between health-
care providers and researchers, members of
the public (including patients, carers and
people who use health and social care ser-
vices) and members of organisations repre-
senting service users.1 This participation
ensures research is applicable to patients,
and therefore, increases the likelihood that
research ﬁndings will translate into clinical
practice2 as well as addressing the ethical
and political requirements of PPE within
healthcare research.3 4 Involving patients in
the management of their healthcare is widely
recognised to improve quality of care, patient
safety and health outcomes.5–8 However, PPE
can be expensive and, if not rigorously
undertaken with appropriate methodologies,
there is a risk of reducing it to a mechanistic
‘paper exercise’ that restricts the quality of
information generated from the process.4
Ocloo et al9 in their recent narrative review
Strengths and limitations of this study
▪ This article presents the use of sequential simu-
lation (SqS) as a tool for public and patient
engagement in new point-of-care diagnostic
testing strategies.
▪ SqS allows participants to appreciate the patient
journey, including the possible downstream
pathway consequences of introducing new diag-
nostic strategies.
▪ This shared immersion of patients, publics and
researchers allows coconstruction of knowledge
that will guide future research, evidence gener-
ation and policy.
▪ Patient engagement necessitates voluntary par-
ticipation and convenience sampling was
unavoidable.
▪ The test device under evaluation is at a relatively
early stage of development and therefore the
SqS scenarios were based on assumptions.
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of patient and public involvement (PPI) in health-
care call for ‘models and frameworks that enable power
and decision-making to be shared more equitably with
patients and the public in designing, planning and
co-producing healthcare’.
PPE is particularly important in the implementation
of innovation and healthcare delivery improvements.10
Technology advancement such as new diagnostics play
an important role in such innovation but development
must be in keeping with patient’s health needs and
expectations.11 12 More tests are making the translation
from the laboratory to point-of-care test (POCT)
devices, creating new diagnostic strategies that may
disrupt traditional clinical pathways. It is rare for a
patient to directly beneﬁt from a diagnostic test in isola-
tion;13 instead the impact comes from the decisions and
interventions that are undertaken as a result of its intro-
duction. Therefore, to allow informed input from public
and patients into the research and development of novel
diagnostic tests, the test process and any subsequent
effects to downstream clinical pathways must be
demonstrated.
Sequential simulation (SqS) is a tool that demonstrates
key elements in a patient’s journey and can highlight
the consequences of intervention at each step. SqS work-
shops can provide an innovative framework for PPE,
especially when aligned to the four key assumptions of
the Shared Immersion Model as described by Tang
et al:14
▸ Public engagement activities can be experiential,
involving participation as well as acquisition of
information
▸ The shared experience constitutes an event
▸ Being immersed in the shared experience is central,
for researchers and publics alike. Critical evaluation
of this process is equally valuable for both
▸ Simulation can provide immersive engagements
between science and publics, especially with health-
care activity and research
Simulation has previously been used by our group as a
tool for engagement with integrated care,15 multidiscip-
linary teams and adolescents16 and for surgical
devices.17 In the ﬁrst two examples, SqS addressed clin-
ical care pathway redesign; while in the latter, the focus
was on the use of novel devices in healthcare environ-
ments. The current study combines these two
approaches to facilitate PPE in the development of
POCT diagnostics by exploring the stakeholder perspec-
tive on a new diagnostic test device and investigating its
potential impact on the patient’s journey.
The aim of this study is to introduce, through a case
study, SqS as a methodology for active PPE in the devel-
opment of novel POCTs and appraise the approach.
CASE STUDY
Oesophagogastric (OG) cancer represents the fourth
and ﬁfth most common types of cancer death.11 Each
year in England, 12 900 people are diagnosed with OG
cancer and of these only 37.3% are considered curable
at the time of diagnosis.11 12 However, when diagnosed
at its earliest stage, the 1-year survival is 75–87%.11
Public awareness of these cancer types is poor and the
symptoms (dyspepsia (heartburn or indigestion), dys-
phagia (difﬁculty swallowing), unexplained weight loss,
persistent vomiting, tiredness (anaemia) and upper
abdominal pain) are common and often not associated
with cancer.10 This leads to a delay in presentation to
healthcare services and therefore treatment. In view of
this, National Health Service (NHS) England recently
undertook a ‘Be Clear on Cancer’ campaign for OG
cancer targeting patients with heartburn and indiges-
tion.18 Within our department, research is investigating
the use of volatile organic compounds (VOCs) for early
OG cancer diagnosis. Previous experimental work has
demonstrated that exhaled breath analysis using mass
spectrometry can distinguish oesophageal and gastric
adenocarcinoma from non-cancer controls,19 demon-
strating the potential for a VOC-based breath test to
provide point-of-care risk stratiﬁcation for patients with
suspected OG cancer. This new approach aims to
provide a readily available, non-invasive and cost-effective
test to streamline patients with the early symptoms of
cancer to further investigation with endoscopy. It is
hoped that by increasing the number of patients diag-
nosed early, a higher proportion of these patients will
have early stage disease and be able to enter a treatment
pathway with curative intent. Much remains to be learnt
about the social, cultural and practical implications of
this new technology.
METHODS
Three 3-hour workshops were undertaken in central
London. For workshop 1, we invited members of the
Oesophageal Patients Association through their mailing
list and social media, providing access to participants
with prior experience of OG cancer and its diagnostic
pathway, either personally or as a relative or carer.
Workshops 2 and 3 were aimed at the general public
without previous experience of OG cancer. Recruitment
to workshop 2 was through an open invitation advertised
in venues local to the workshop, and in workshop 3 a
focus group recruitment ﬁrm (Focus4People, Herts,
UK) was used.
The three workshops followed the same structure and
comprised presentations, clinical pathway SqS and facili-
tated group discussions. Following a brief introduction to
the day, a presentation covering the background to OG
cancer including the current diagnostic strategy was
given. This led into the ﬁrst clinical pathway simulation—
a scenario that was designed to represent a relatively
common patient journey. It was unscripted and followed
a storyboard of a patient, played by a professional actor,
noticing the symptoms of an oesophageal cancer and
undergoing a typical diagnostic pathway (ﬁgure 1). The
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storyboards were designed to represent a ‘typical’ uncom-
plicated diagnostic pathway for a patient with oesopha-
geal cancer and created in consultation with specialist
clinicians. To validate the storyboard participants with a
personal experience of OG cancer, were asked to feed-
back on how the scenario related to their own experi-
ences during the ﬁrst workshop. Actors were used to
ensure a personalised approach to the scenario, while
maintaining conﬁdentiality and ensuring consistency
across workshops. Clinicians played their own healthcare
roles in the simulation scenarios. The clinicians also
respond well to actors who appear very realistic. The sets
were created using distributed simulation20—versatile
transportable screens and props including beds, desks
and medical equipment (ﬁgure 2). The simulation scen-
ario was followed by the workshop breaking down into
small groups (5–10 people) for facilitated table discus-
sions regarding the current diagnostic pathway. The
groups were then brought back together and table discus-
sions were summarised in a plenary session. After a coffee
break, a member of the research team gave a presenta-
tion describing the current research achievements in lay
terms and introduced the concept of the novel breath
test, as well as our future ambitions. A second SqS fol-
lowed the same patient through his journey, although
this time we incorporated the breath test into the scen-
ario to demonstrate the potential downstream conse-
quences to the clinical pathway. Again, small table
discussions followed.
Participants completed pre-event (see online supple-
mentary appendix 1) and postevent (see online supple-
mentary appendix 2) questionnaires that included a
series of statements regarding attitudes and feedback
related to the novel test device and also on the SqS
workshop experience itself that participants were asked
to rate on a 5-point Likert scale (strongly disagree to
strongly agree). Participants were given copies of presen-
tation slides and contact details if they would like to
discuss anything from the workshop further.
The workshop discussions were ﬁlmed and recorded
for subsequent analysis. Workshop recordings were tran-
scribed and emergent thematic analysis undertaken
independently by two members of the research team
( JRH and SR), who were not directly involved in the test
device research. Qualitative data were analysed with
NVivo V.10.1.1 software (QSR International, Melbourne,
Australia). Ethical approval for the workshops was pro-
vided by the Imperial College Joint Research
Compliance Ofﬁce (reference number ICREC_11_5_8)
Figure 2 Sequential simulation (SqS) sets to illustrate (i) the
patient’s home (ii) an endoscopy unit and (iii) general practice
consultation.
Figure 1 Storyboard of diagnostic pathway for
oesophagogastric cancer used in sequential simulation
scenarios. GP, general practitioner; POC, point-of-care.
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and informed consent was obtained from all workshop
participants.
RESULTS
In total, 38 participants attended the 3 workshops, 26
(68%) of whom had no previous experience personally
or as a relative or carer of the OG cancer diagnostic
pathway. A total of 12 participants were recruited
through the Oesophageal Patients Association, of which
11 (92%) attended; 14 participants replied to public
poster and email campaign, of which 8 (57%) attended;
and 20 patients were recruited by the focus group
recruitment company, of which 19 (95%) attended. Two
participants have subsequently volunteered to contribute
further to our research activities and now have a role in
PPI within the group.
Thematic analysis of workshop audio recordings
Two analyses were undertaken: (i) an analysis of partici-
pant attitudes towards the use of SqS for PPE in POCT
diagnostics; and (ii) an analysis of patient feedback
regarding the breath test device, diagnostic strategy and
clinical pathway.
Three themes emerged regarding the use of SqS for
public engagement in novel POCT diagnostic test:
participatory engagement, simulation and empathetic
engagement, and why participants attended. Theme
summaries and quotations from transcripts are included
in table 1.
In respect to the diagnosis of OG cancer and the pro-
posed new breath test and diagnostic test strategy, ﬁve
themes emerged from the workshop: awareness of OG
cancer, barriers to testing and diagnosis, design of new
test device, new clinical pathway and placement of test
device. Theme summaries and participant quotations
are presented in table 2.
Table 3 demonstrates the ‘co-construction of knowl-
edge’ document. This collective output of shared experi-
ences from researchers, patients and public summarises
the key outputs raised from the workshops with pro-
posed solutions to guide future research and implemen-
tation strategies.
Participant feedback questionnaire
All patients completed a questionnaire at the start and
on completion of the workshop.
Feedback relating to the SqS workshop experience is
shown in ﬁgure 3. All patients reported they felt able to
contribute to the discussion (strongly agree n=31 (82%);
agree n=7 (18%)), that presentations were at a level they
were able to understand (strongly agree n=32 (84%);
Table 1 Summary of themes relating to use of sequential simulation for public engagement in novel diagnostics
Key themes
identified Summary Quotations from transcript
Participatory
engagement
All participants actively contributed to small group
discussions that often overran and continued into
breaks and over lunch.
‘We were made comfortable to contribute’. W2
‘Feeling that the patient perspective is important
in achieving better results’. W2
Simulation and
empathetic
engagement
Participants felt the simulations gave structure to
the events allowing them to focus on the
simulated patients’ journey and understand the
consequences of the new diagnostic strategies.
Participants who had been through the diagnostic
pathway of OG cancer commented how similar it
was to their experiences although there were
some comments that the pathway was
oversimplified in some areas, for example, ease of
access to GP appointment and ease in which the
GP undertook the test within a consultation.
‘The process I just watched echoed exactly what I
experienced when I was diagnosed’. W1
‘The simulation of patient/GP scenarios to add
context’. W2
‘It really stays in your mind, you know, you have a
picture’. W2
‘It makes it more real’. W2
Why participants
attended
Attendance at the workshops was linked to the
method of recruitment. In the second workshop
that was recruited through advertisements in the
local areas (see methods), we explored the
motivation for attendance. This was broadly
divided into those with a community interest in
new diagnostic and medical developments and
those that had experience of cancer either
personally or as family or carers and wanted to
learn more and contribute to research in this area.
‘I am interested in this way of, it’s not only
researchers and doctors thinking about how to
develop it, but they are also listening carefully to
how people would feel with these new
developments’. W2
‘This (workshop) interested me because as it just
so happens last year I had three gastroscopies
and I know what they feel like’ W2
‘I organize health workshops with community
development, with community organisations, we
work in the local community and we stress
prevention and that sort of thing’. W2
W1, W2 or W3 denotes workshop where quotation was made.
GP, general practitioner; OG, oesophagogastric; W, workshop.
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Table 2 Summary of themes relating to current and novel diagnostic strategy for Oesophago-gastric cancer
Key themes identified Summary Quotations from transcript
Awareness of
oesophagogastric
cancer
There was general agreement regarding the
lack of awareness of OG cancer, it’s symptoms
and the poor outcome. There was a strong
feeling of a need for awareness campaigns
including celebrity endorsement and social
media. The role of the media in raising
awareness was discussed, and it was felt that
over the counter antacid medications should
contain warnings of the disease.
‘It needs to be more like colorectal cancer
because people know if they have blood in their
stools it’s a worrying sign and straight away they
go to their GP’. W1
‘Media really important’! W2
‘GPs see this condition rarely compared with
other cancers’. W1
‘If you are buying so and so amounts of
Gaviscon this could be a sign (of cancer)…
please check with your GP’. W3
‘I didn’t realise there was such a cancer at such
a low survival rate’. W3
Barriers to testing and
diagnosis
There were many barriers highlighted to the
current diagnosis of OG cancer; these included
the anxiety, invasiveness, cost and
complications of endoscopy, lack of education,
cultural reluctance to seeking medical advice
particularly among men in at risk age groups,
difficulty in accessing primary care services,
delayed recognition of potential cancer and
subsequent referral by GPs and hospital delays
for investigation.
‘Males more difficult to get to present and further
awareness needed and less-invasive options’.
W2
‘How invasive the current test is could put a lot
of people off’. W1
Design of new test
device
A potential urine test and breath test were
acceptable, but overall most participants would
prefer a breath test. There was a preference for
a compact box like test similar to a police
breathalyser (offers familiarity). Participants
would rather see the test launched early and
not delayed for attempts to improve accuracy.
How the test provided results was a
controversial topic with some participant
preferring a quantitative result, for example, a
risk percentage, some would prefer to have
triage-like results, for example, high risk or low
risk. A pure binary result, for example, red light/
green light was not popular as it was felt this
would increase anxiety. What overrides these
discussions was that the practitioner delivering
the result should be appropriately trained to
explain the meaning of the result and council
regarding further management and privacy and
support need to be provided. Written
information was not felt to be sufficient and the
inclusion of a nurse was highlighted as
beneficial.
‘It is important that people are trained to give out
the result appropriately’. W1
‘The simpler, the better’. W1
‘Person giving results has to be able to quantify
the risk (eg, percentage chance) of cancer when
they give the test result—“high-risk” is too
vague’. W1
‘It is important that people are trained to give out
the results appropriately’. W1
‘I actually liked the box with a mouthpiece rather
than a plastic bag’. W3
‘I don’t mind what kind of test as long as it’s
accurate’. W3
‘Needs to be brought to market faster’
New clinical pathway There was an overall positive response to the
proposed new pathway incorporating the
potential breath test device. Participants felt that
increasing access and convenience to
diagnosis would encourage uptake, particularly
in a non-invasive test device. There was some
concern that a positive breath test would
increase anxiety preceding endoscopy, but this
was felt to be unavoidable and would always
occur in cancer diagnostic pathways and may in
fact increase the uptake of subsequent
endoscopy. It was important that patients with a
negative breath test know to return to their GP,
if symptoms do not improve.
‘Something before the invasive endoscopy test
would encourage people more’. W1
‘If there was a recurring acid problem and the
breath test was negative I would probably want
to go for an endoscopy’. W3
‘The anxiety has to come at a point so maybe
he just has to go through it earlier’. W1
Continued
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agree n=6 (16%)) and that the day was a useful experi-
ence (strongly agree n=31 (82%); n=7 (18%)). The
majority of participants felt that diagnostic test devices
will be better if patients are involved in their develop-
ment (strongly agree n=26 (68%); agree n=8 (21%);
neither agree or disagree n=3 (8%); disagree n=1 (3%)).
Feedback relating to the breath test strategy is shown in
ﬁgure 4. All patients liked the idea of a breath test for OG
cancer (strongly agree n=32 (84%); agree n=6 (16%))
and stated they would like a breath test before an endos-
copy (strongly agree n=36 (95%); agree n=2 (5%)). The
majority of patients did not agree that the breath test
would add to their anxiety (agree n=2 (5%); neither
agree or disagree n=7 (18%); disagree n=10 (26%);
strongly disagree n=16 (42%); 3 (8%) did not answer)
and agreed that a ‘low-risk’ result from the breath test
would provide reassurance without specialist referral
(strongly agree n=7 (18%); agree n=19 (50%); neither
agree or disagree n=9 (24%); disagree n=3 (8%)).
DISCUSSION
SqS workshops provided an effective immersive environ-
ment for public and patient engagement around device
development and future diagnostic strategy, creating a
shared experience that was beneﬁcial to participants
Table 2 Continued
Key themes identified Summary Quotations from transcript
Placement of novel test
device
Most participants felt the test should be placed
in either a GP surgery or a pharmacy. Other
proposed testing locations were:
▸ Public places for ‘drop-in’ testing
▸ Workplace testing
▸ Health fairs
▸ Mobile testing to ‘at-risk’ populations
▸ Booths in GP practices
▸ Home testing
‘If there is an easy test maybe it should be
available in a more accessible place than the
GP practice’. W1
‘If the test is to be used in a pharmacy perhaps
just having high risk or low risk is sufficient, or
perhaps just that you need to have more tests or
you don’t’. W1
‘Are we going to have the approach like the
radiographers that do imaging and then say they
can’t interpret the results and you will go to your
(doctor’s) appointment’. W1
W1, W2 or W3 denotes workshop where quotation was made.
GP, general practitioner; OG, oesophagogastric; W, workshop.
Table 3 Coconstruction of knowledge from researcher–participant shared experience
Issues raised Solutions
Poor awareness of OG cancer ▸ Better media campaigns (a media campaign was initiated by NHS
England during the course of this study), involvement of celebrities
and social media
▸ Highlighting symptoms of OG cancer on antacid medication packets
akin to health warnings on cigarette packaging
Invasiveness and risks of endoscopy deterring
patients presenting to medical services
▸ Breath test could triage for endoscopy
▸ Improve cost-effectiveness of patient journey
Breath test device design ▸ Preference for compact (box like) simplistic breath test over urine
▸ Significant number of people not concerned about aesthetic
appearance
▸ Preference for breath test over urine
Positioning of test: pharmacy versus GP ▸ Preference for pharmacy for ease of access and speed in which test
can be done
▸ Concerns regarding meaning of test result and how it will be
explained to patients
▸ Hybrid options such as test being undertaken in pharmacy and result
explained by GP/hospital doctor at a later date
Delivery of test results and impact on patients ▸ Professional delivery of breath test results including quantification,
explanation of future expectation will require, excellent communication
skills and relevant knowledge
▸ Training for all involved will be essential
▸ GPs likely to have optimum skill set to achieve this
GP, general practitioner; OG, oesophagogastric; NHS, National Health Service.
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and researchers. Rich data provide feedback on research
activities to date and will help guide future research
activities.
The outputs from the current workshops have already
inﬂuenced future research plans regarding the VOCs
breath test for OG cancer as follows: identifying a
broader scope of where the test could be located,
including general practice, pharmacies and workplaces;
how the test result is presented to manage associated
patient anxiety; and the migration from currently used
breath bags to sensor technology. The workshops con-
ﬁrmed patient acceptability of the proposed breath
testing strategy for cancer diagnosis and reinforced the
lack of awareness that exists with regard to OG cancer
and its symptoms.21 Furthermore, the workshop outputs
have provided valuable information to other stake-
holders concerned with POCT invention and adoption,
including device designers, clinicians, commissioners
and policymakers. As such, we believe results from PPE
activities should be routinely published alongside clinical
studies and cost-effectiveness arguments as part of a
complete evidence package.
The largest challenge in running the workshops was
recruitment. Three strategies were trialled, providing an
opportunity to weigh the beneﬁts and challenges of
each and to recruit different participants with different
backgrounds and motivations. The professional focus
group recruitment ﬁrm was convenient and allowed the
tailoring of the group to ensure a representative sample.
However, this entailed greater cost as a recruitment
Figure 3 Participant questionnaire feedback relating to the sequential simulation (SqS) workshop experience.
Figure 4 Participant questionnaire feedback relating to the novel breath testing strategy for the diagnosis of oesophagogastric
cancer. GP, general practitioner.
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commission was paid to the company. Recruitment to
workshop 1 was also straightforward as replies to invita-
tions sent to members of the Oesophageal Patients
Association were forthcoming. Workshop 2 provided the
greatest challenge in recruitment, requiring members of
the research group to explore the locality of the work-
shop venue and placing posters in a variety of venues to
encourage interest. Response rate was low, and there was
a high rate of non-attendance on the day.
Other costs associated with running the workshops
were venue hire including refreshments and lunch, pro-
fessional actor fees, scenery and props for the simulation
scenarios, and transport of equipment. PPI workshops
do have an associated cost, for these three events we
allocated a budget of £12 000 (although this included
the purchase of equipment that can be reused in subse-
quent events); it is therefore vital that the cost of PPE
activities be incorporated into research budgets and
funding applications.
This methodology does have limitations. Patient
engagement necessitates voluntary participation, and
convenience sampling was unavoidable. By varying the
recruitment strategy, incentives for attendance and previ-
ous knowledge of OG cancer, we hope to have achieved
an overall representative sample in the course of the
three events, although sociocultural and clinical
characteristics of participants were not recorded.
Screening participants for their level of engagement
using the Patient Health Engagement Scale22 or Patient
Activation Measure6 would have provided a useful
measure to interpret the comments of participants. The
transcripts from the events were analysed by two
researchers who were not directly involved with the
development of the breath test or VOC research, mini-
mising bias in emergent theme analysis. Finally, the test
device under evaluation is at a relatively early stage of
development and therefore the scenarios were based on
assumptions.
Patient engagement is vital at this early stage to guide
device development, ensure the proposed clinical
pathway is acceptable to patients and guide future
research activities. To be effective, patient engagement
must not be seen as an isolated event and needs to con-
tinue alongside evidence generation and device develop-
ment to improve the acceptability of POCT.
The value of PPE is increasingly recognised in the
development of medical devices and care pathways.
Barello et al,7 in their systematic review of eHealth for
Patient Engagement, describe PPE as multidimensional
with behavioural, cognitive and emotional components.
The review concludes that the majority of approaches to
PPE do not facilitate engagement at all three levels.
However, SqS is able to provide a holistic and systematic
approach that fulﬁls all three as described in the shared
immersion model14 through the participant’s role in the
experience (emotional), evaluation (cognitive) and par-
ticipation in the ongoing process of device development
(behavioural). Furthermore, the nature of the shared
event allows a degree of empathy between all stake-
holders present, so that the outputs from the workshops
can truly be underpinned in further research and device
development.
In conclusion, SqS provides an effective methodology
for active public and patient engagement and, to a
limited degree, involvement in research towards the
development of new POCT diagnostic devices and
testing strategies. The outputs of these events provide
rich data that can be of use to a wide range of stake-
holders and could form a routine part of the evidence
base, informing the adoption of new POCT devices.
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